Real-World Data in Cardiology: Focus on Atrial Fibrillation

Slides:



Advertisements
Similar presentations
ARISTOTLE Objectives Primary: test for noninferiority of apixaban, a novel oral direct factor Xa inhibitor, versus warfarin Secondary: test for superiority.
Advertisements

Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Beta-Blockers and Outcome in Heart Failure and Atrial.
Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: Effect of Obstructive Sleep Apnea Treatment on Atrial.
Addressing the Challenges in Primary and Secondary Stroke Prevention
Covering the Bases in Cardioversion
Burden of Atrial Fibrillation The Percentage of Strokes Attributable to AF Increases With Age.
Anticoagulant Safety Remains a Problem Emergency Hospitalizations for Adverse Drug Events.
Monitoring Continuum ISSUE-3 Atrial Fibrillation Classification.
Atrial Fibrillation and PCI
Updates in Anticoagulation: What Did We Learn From ESC 2017?
Long-Term Treatment of VTE: Case Studies
US Guidelines US Guidelines Low-risk Patients.
When Is Adding Aspirin to NOACs Worth the Risk?
Barriers to Oral Anticoagulant Use for Stroke Prevention in AF
Thrombosis, Cancer, and NOACs
Access to NOAC Therapy:
NOACs in Clinical Practice: Are They All the Same?
Overall burden of AF associated with higher risk of thromboembolism and ischemic stroke An analysis of the KP-RHYTHM study, in patients with paroxysmal.
Appropriate Stroke Prevention Strategies in Atrial Fibrillation
Introduction ESC Annual Meeting in Review: NOACs and NVAF: Real-World Data, Guidelines, and More.
Anticoagulation Highlights From the American Heart Association Meeting 2017.
Managing Complex Hypertension: What Every Physician Should Know
Oral Anticoagulants in AFa,b A Brief History.
Surveying the Safety of NOACs in the Real World
Selecting NOACs for High-Risk Patients
A Call to Action on Cryptogenic Stroke
NOAC Use in AF: REAL-WORLD Studies WITH REAL RESULTS
How to Adjust Anticoagulant Dosing
Revealing Characteristics of Patients at High Risk for Developing Atrial Fibrillation.
The Essentials for Secondary Stroke Prevention
Stroke and AF.
Assessing the Risk for Stroke in Patients With Atrial Fibrillation
Real-World Safety of NOACs: What Do We Know Today?
Applying Real-World Evidence in Atrial Fibrillation Into Clinical Care:
Efficacy and Safety of Edoxaban in Patients With AF and HF
Access to NOAC Therapy:
Adherence in SPAF: Measures to Improve Care
Catheter Ablation for the Cure of Atrial Fibrillation Study
What Anticoagulant Registries Are Revealing
Learning Objectives Classification of VTE Goals of VTE Treatment.
VTE in Cancer.
Oral Anticoagulation in AF
Practical Considerations to Extend Treatment for VTE
Atrial Fibrillation.
Extraordinary Cases of VTE Prevention in Patients With Cancer
Taking the "Cryptogenic" Out of Cryptogenic Stroke
NOACs in AF: Consequences of Underdosing and NonAdherence
Anticoagulation and Thrombosis Management
Assessing Atrial Fibrillation: Real-World Data vs Clinical Trials
Trials and Tribulations in VTE: How Do Real-World Data Fit In?
Long-Term Treatment of VTE: Case Studies
A Time for Change for Managing Patients With VTE Who Have Cancer
What You Didn't Know About AF and Renal Dysfunction
Cancer-Associated Thrombosis
New European Anticoagulant Approvals Will They Affect Practical Guidance?
Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?
Updates in Anticoagulation: Key Sessions at ESC 2017
Managing Pulmonary Embolism Posthospital Discharge
Antithrombotics in Arterial Disease: Focus on Coronary Disease
NOACs in AF: Consequences of Underdosing and NonAdherence
Taking the "Cryptogenic" Out of Cryptogenic Stroke
5 Good Minutes on Atrial Fibrillation-related Stroke
VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.
Updates on Dyslipidemia
How to Adjust Anticoagulant Dosing
Antiarrhythmic Drugs in AF
Uptitration of Medications in HF: Start Low but Aim High and Stay High
Overall burden of AF associated with higher risk of thromboembolism and ischemic stroke An analysis of the KP-RHYTHM study, in patients with paroxysmal.
Extraordinary Cases in Stroke Prevention
What's New in NOACs in AF?.
Presentation transcript:

Real-World Data in Cardiology: Focus on Atrial Fibrillation

Program Goals

NOACs in Stroke Prevention in AF

What Is Real-World Evidence?

Types and Sources of Real-World Evidence

Types and Sources of Real-World Evidence (cont)

Uses of Real-World Evidence

Uses of Real-World Evidence (cont)

XANTUS

XANTUS Pooled Analysis

XANTUS Major Outcomes

XANTUS Treatment Persistence

GARFIELD-AF

GARFIELD-AF (cont)

Drug Use Patterns

Drug Adherence

US Database Renal Dosing

US Database Renal Dosing (cont)

XANTUS Inappropriate Dose Reductions

Renal Function Must Be Monitored

Summary

Abbreviations